These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37587797)

  • 21. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V; Oliver S; Su CA
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative and absolute bioavailability of cibenzoline capsules and tablets in healthy subjects.
    Massarella J; Silvestri T; Lin A
    J Pharm Sci; 1986 Sep; 75(9):894-6. PubMed ID: 3783460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
    Cheng Y; Liu L; Xue Y; Zhou S; Li Y
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
    Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.
    Sun H; Ting L; Machineni S; Praestgaard J; Kuemmell A; Stein DS; Sunkara G; Kovacs SJ; Villano S; Tanaka SK
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7431-7435. PubMed ID: 27736760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absolute bioavailability of quinine formulations in Nigeria.
    Babalola CP; Bolaji OO; Ogunbona FA; Ezeomah E
    Afr J Med Med Sci; 2004 Sep; 33(3):185-9. PubMed ID: 15819461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.
    Krishna G; Ma L; Martinho M; O'Mara E
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4196-201. PubMed ID: 22615291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase.
    Cheng Y; Liu L; Xue Y; Zhou S; Li Y
    J Clin Pharm Ther; 2022 Aug; 47(8):1186-1193. PubMed ID: 35307850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, Dose Proportionality, and Bioavailability of Bazedoxifene in Healthy Postmenopausal Women.
    McKeand W
    Clin Ther; 2017 Sep; 39(9):1769-1779. PubMed ID: 28756067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets.
    Coupez R; Straetemans R; Sehgal G; Stockis A; Lu ZS
    J Clin Pharmacol; 2003 Dec; 43(12):1370-6. PubMed ID: 14615473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.
    Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N
    Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
    Naing A; Kurzrock R; Adams LM; Kleha JF; Laubscher KH; Bonate PL; Weller S; Fitzgerald C; Xu Y; LoRusso PM
    Invest New Drugs; 2012 Feb; 30(1):327-34. PubMed ID: 20842406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
    Kakuda TN; Leopold L; Timmers M; Van De Casteele T; Hillewaert V; Tomaka FL; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):805-16. PubMed ID: 25109510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
    Menssen HD; Quinlan M; Kemp C; Tian X
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):385-394. PubMed ID: 30059193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers.
    Chen L; Krekels EHJ; Heijnen AR; Knibbe CAJ; Brüggemann RJ
    Drugs; 2023 Jan; 83(1):75-86. PubMed ID: 36607589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.
    Juif PE; Hoch M; D'Ambrosio D; Dingemanse J
    Drugs R D; 2015 Jun; 15(2):203-10. PubMed ID: 25939333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
    Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
    Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.